Zanotti et al., 2021 - Google Patents
Systemic mastocytosis: multidisciplinary approachZanotti et al., 2021
View HTML- Document ID
- 1521584206299843053
- Author
- Zanotti R
- Tanasi I
- Crosera L
- Bonifacio M
- Schena D
- Orsolini G
- Mastropaolo F
- Tebaldi M
- Olivieri E
- Bonadonna P
- Publication year
- Publication venue
- Mediterranean Journal of Hematology and Infectious Diseases
External Links
Snippet
Systemic mastocytosis (SM) is a heterogeneous group of diseases that affect almost exclusively adults and are defined by the proliferation and accumulation of clonal mast cells (MC) in various tissues. Disease subtypes range from indolent to rare aggressive forms …
- 201000008736 systemic mastocytosis 0 title abstract description 165
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zanotti et al. | Systemic mastocytosis: multidisciplinary approach | |
| US20230083487A1 (en) | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent | |
| US20200024355A1 (en) | Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment | |
| Tefferi et al. | Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update | |
| Chen et al. | Advances in the diagnosis and treatment of Sjogren’s syndrome | |
| Lin et al. | Aberrant human leucocyte antigen‐G expression and its clinical relevance in hepatocellular carcinoma | |
| US9688761B2 (en) | Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies | |
| JP2021502071A (en) | Cancer biomarkers and how to use them | |
| Suelves et al. | Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients | |
| Zoet et al. | Cardiovascular RiskprofilE-IMaging and gender-specific disOrders (CREw-IMAGO): rationale and design of a multicenter cohort study | |
| Valent et al. | Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT | |
| JP2016540993A (en) | Protein biomarkers and uses thereof | |
| Pape et al. | Oncological treatments have limited effects on the fertility prognosis in testicular cancer: A systematic review and meta‐analysis | |
| Zanotti et al. | Systemic mastocytosis: multidisciplinary approach. Mediterr J Hematol Infect Dis. 2021; 13 (1): e2021068 | |
| Jo et al. | NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma | |
| Bonadonna et al. | Mast cell disorders in drug hypersensitivity | |
| US8642274B2 (en) | Immunotherapeutic method | |
| Bijl et al. | Vaccination of the immune-compromised patients with focus on patients with autoimmune-inflammatory diseases | |
| Moustafa et al. | Eltrombopag-Induced Myelofibrosis in Patients with Adult Immune Thrombocytopenia: Scoping Review | |
| EP4153783A1 (en) | Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma | |
| Velloso et al. | Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | |
| Jamuna et al. | Current approaches in the diagnosis and management of non-small cell lung cancer brain metastases | |
| George | Technical challenges of applying artificial intelligence (AI) on psoriasis images for automated PASI assessment | |
| Fardell et al. | Health Behaviours in Survivors of Childhood Cancer: Modifiable Risk Factors for Developing Late Effects | |
| Stawinski et al. | S341 Implementation of a Direct Access Colonoscopy Program in a Resident-Run Continuity Clinic: A Real-World Experience |